0 CHECKOUT
Ulcerative Colitis: KOL Insights on Treatment Practices and Unmet Needs Product Image

Ulcerative Colitis: KOL Insights on Treatment Practices and Unmet Needs

  • ID: 1780462
  • April 2011
  • 110 Pages
  • Sociable Pharma

FEATURED COMPANIES

  • Alaven
  • AstraZeneca
  • Centocor
  • Forest
  • Merck
  • Prometheus
  • MORE

The use of biologics is still in its formative stages in the treatment of ulcerative colitis but adoption has already been significant and is set to expand considerably in the short- and medium-term. Sociable Pharma conducted in-depth primary research in the US and Europe with key opinion leaders to understand how these changes will impact therapy use in the future. Opinion was also gauged during the European Crohn's & Colitis Organisation's (ECCO) Annual Congress on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by inflammatory bowel disease specialists.

Report highlights:

- Identifies the latest treatment trends in Ulcerative Colitis, including the role of biologics in steroid-refractory patients and acute/severe settings
- Based on key opinion leader interviews in the US and Europe, as well as the ECCO 2011 conference, supplemented with extensive secondary research on medical evidence and guidelines
- Analyzes current treatment practices covering five major drug classes: aminosalicylates (5-ASAs), corticosteroids, immunomodulators, anti-TNF therapies, calcineurin inhibitors
- Highlights opinion READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Alaven
  • AstraZeneca
  • Centocor
  • Forest
  • Merck
  • Prometheus
  • MORE

Executive Summary

Scope of analysis & methodology



Current treatment practice

– Corticosteroids

– Aminosalicylates

– Immunomodulators

– Anti-TNF therapies

– Calcineurin inhibitors

Treatment challenges & unmet needs



Treatment Map

Note: Product cover images may vary from those shown

- AstraZeneca
- Prometheus
- Forest
- UCB Pharma
- Ferring
- Shire
- Warner Chilcott
- Salix
- Alaven
- Axcan
- Pfizer
- Almirall
- GSK
- Centocor
- Merck

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS

Our Clients

  • Amgen Inc.
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Beckman Coulter, Inc.
  • Novartis AG
  • Baxter International Inc.